Claims for Patent: 7,468,266

Summary for Patent: 7,468,266

Title:	Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
Abstract:	The invention is directed to isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human lipoprotein-associated phospholipase A2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s):	Ryan; James W. (Augusta, GA)
Assignee:	Ryogen, LLC (Suffern, NY)
Application Number:	10/161,127
Patent Claims:	1. An isolated genomic polynucleotide selected from the group consisting of: (a) a polynucleotide which is at least 99% identical to the polynucleotide of SEQ ID NO:2, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has human lipoprotein-associated phospholipase A2 activity; (b) a fragment of (a) comprising at least nucleotides 11967-30301, which encodes a polypeptide which is at least 99% identical to the amino acid sequence of SEQ ID NO:1, wherein said polypeptide has lipoprotein-associated phospholipase A2 activity; and (c) the full complement of (a) or (b). 2. A nucleic acid construct comprising the polynucleotide of claim 1. 3. An expression vector comprising the polynucleotide of claim 1. 4. A recombinant host cell comprising the isolated polynucleotide of claim 1. 5. A method for obtaining a polypeptide encoded by the polynucleotide of claim 1, wherein said polypeptide is at least 99% identical to the amino acid sequence SEQ ID NO:1, wherein said polypeptide has lipoprotein-associated phospholipase A2 activity, by (a) culturing a recombinant host cell comprising the polynucleotide of claim 1 under conditions that provide for the expression of said polypeptide and (b) recovering said expressed polypeptide. 6. A composition comprising the polynucleotide of claim 1 and a carrier. 7. A method for modulating human lipoprotein-associated phospholipase A2 levels in a subject in need thereof, comprising administering to said subject an amount of the composition of claim 6 effective to modulate said human lipoprotein-associated phospholipase A2 levels in said subject. 8. An isolated polynucleotide selected from the group consisting of (a) SEQ ID NO:2, which encodes lipoprotein-associated phospholipase A2 of SEQ ID NO:1; (b) a fragment of (a) comprising at least nucleotides 11967-30301 of SEQ ID NO:2, which encodes lipoprotein-associated phospholipase A2 of SEQ ID NO:1 and (c) the full complement of (a) or (b). 9. An isolated polynucleotide probe or primer consisting of a non-coding region of the polynucleotide of claim 1, which non-coding region is selected from the group consisting of a 5' non-coding region shown in sequence segment 1-11966 of SEQ ID NO:2, an intron shown in sequence segments 12072-17760, 17887-18332, 18477-20306, 20400-22521, 24317-25442, 25533-26697, 26869-29557 and 29708-30163 of SEQ ID NO:2 and a 3' non-coding region shown in sequence segment 30302-42611 or reverse strand of said polynucleotide. 10. A method of identifying a polynucleotide of SEQ ID NO:2, which encodes a lipoprotein-associated phospholipase A2 of SEQ ID NO:1, or its complementary sequence comprising: (a) isolating genomic DNA from a subject and (b) determining the presence or absence of a polynucleotide identical to the polynucleotide of SEQ ID NO:2 in a subject by comparing the nucleotide sequence of SEQ ID NO:2 with the nucleotide sequence of the isolated genomic DNA.

Details for Patent 7,468,266

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-05-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-05-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-05-30